Active	Status	Sponsor type	Region	Phase	Filter
4 Active 8 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chi, Yihebali
NCT06540937: Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor	Recruiting	2	50	RoW	Leflunomide Pill, Leflunomide 20mg	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Neuroendocrine Tumors	12/24	12/24
NCT05204524: Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma	Recruiting	2	28	RoW	Temozolomide for injection combined with epirubicin	Chinese Academy of Medical Sciences	Leiomyosarcoma	08/22	08/23
NCT06038461: An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors	Recruiting	1/2	40	RoW	Surufatinib Combined With Temozolomide and S-1	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Neuroendocrine Tumors	09/26	09/26
NCT05055518: APL-102 Capsule in Patients With Advanced Solid Tumors	Recruiting	1	30	RoW	APL-102 Capsules, No other name so far	Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd	Advanced Solid Tumor	10/23	12/23